Login to Your Account

Financings Roundup

Another IPO! TVAX Seeks $40M To Fund Cancer Immunotherapy

By Marie Powers
Staff Writer

Wednesday, November 9, 2011
Cancer immunotherapy firm TVAX Biomedical Inc. became the latest biotech to line up this year for an initial public offering, filing an S-1 on Monday and seeking to raise $40 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription